The global allogeneic cell therapy market is estimated to be worth USD 0.9 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 14% during the forecast period 2023-2035. Allogeneic cell therapies refer to off-the-shelf therapies that are isolated from donor tissues (such as cord blood and bone marrow), processed ex vivo in the labs and then administered into patients / cryopreserved in a cell bank. Since these therapies are manufactured in advance, they are readily available and eliminate the need for individualized production for every patient. Owing to their various benefits, such as improved and consistent product quality (due to rigorous quality control measures taken during processing), reduced cost (due to centralized manufacturing process) and flexibility in approaching the same donor or choosing a different donor (in case the patient requires another course of the treatment), allogeneic cell therapies have gained significant traction in the healthcare industry. Further, recent advancements in gene editing technologies, such as CRISPR / Cas9, have opened up new possibilities for allogeneic cell therapies by enabling precise genetic modifications in the donor cells in order to enhance their therapeutic properties and reduce the risk of immune rejection.
Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, including hematological malignancies (such as multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological disorders, musculoskeletal disorders and autoimmune / inflammatory disorders, have received approval from various regulatory authorities, globally. In December 2022, the European Commission approved the first allogeneic T-cell therapy, namely Ebvallo, (developed by Atara Biotherapeutics) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. In addition, the FDA approved an allogenic mesenchymal stem cell therapy, Osteocel® Plus (developed by NuVasive), for the treatment of degenerative disc disease. Driven by the continuous efforts of both industry and non-industry players, rising prevalence of chronic diseases and non-malignant disorders, and challenges associated with production of autologous cell therapies, the global allogeneic cell therapies market is likely to witness substantial market growth during the forecast period.
Key Market Insights
The Allogeneic Cell Therapy Market, 2023-2035 - Distribution by Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell and Regulatory T-Cell), Source of Cell (Peripheral Blood, Bone Marrow, Umbilical Cord Blood, Adipose Tissue and Placenta), Target Indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), Therapeutic Area (Oncological Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune / Inflammatory Disorders and Post-Transplant Infections), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future opportunities for the allogenic cell therapy developers, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the allogeneic therapy market report are briefly discussed below.
Allogeneic Cell Therapy vs Autologous Cell Therapy
Allogeneic cell therapy and autologous cell therapy are two distinct approaches in regenerative medicine market. In autologous cell therapy, the cells are derived from the patient's own body, processed ex-vivo and reintroduced into the same patient; this personalized approach ensures compatibility and minimizes the risk of immune rejection. However, these therapies require a longer production time, as each patient's cells need to be individually processed. On the other hand, allogeneic cell therapy involves the use of cells from a healthy donor; these collected donor cells might be given directly to a genetically similar patient or added to a cell bank. Allogeneic cell therapy has various advantages, including immediate accessibility, scalability and cost-effectiveness, however, it may involve the risk of immune rejection.
Pipeline Analysis: Competitive Landscape of Allogeneic Cell Therapy
Allogenic cell therapy market landscape features the presence of close to 195 large, mid-sized and small companies developing allogeneic cell therapies, for a wide range of indications. It is worth highlighting that over 470 allogenic cell therapies are currently being evaluated in different preclinical / clinical stages, either as monotherapies or in combination with other drugs. In April 2023, Gamida Cell received approval from the FDA for its umbilical cord blood-derived, allogeneic stem cell therapy, Omisirge® (omidubicel-onlv); the therapy is used to treat patients with hematologic malignancies. The growing demand for novel allogeneic cell therapies, approvals from various regulatory bodies and continuous advancements in cell therapy manufacturing process, are expected to drive the allogeneic cell therapies market growth during the forecast period.
Clinical Trials Analysis: More than 365 Trials are Evaluating Allogeneic Cell Therapies to Treat Various Hematologic Malignancies and Solid Tumors
Over the years, companies involved in the development of allogeneic cell therapies have made significant efforts to conduct clinical trials for evaluating the efficacy of allogeneic cell therapies, for the treatment of various disorders, including infectious diseases (adenovirus infection, coronavirus infection and cytomegalovirus infection), neurological disorders (autism, bipolar depression, Parkinson’s disease, stroke) and oncological disorders (acute myeloid leukemia, biliary tract cancer, breast cancer and multiple myeloma). Over 365 clinical trials have been registered across different geographical regions to evaluate various allogenic cell therapies. Of these trials, majority (~180) were registered in North America and maximum number of patients (9,300) were observed to be enrolled in clinical trials conducted in North America, accounting for about 55% of the overall enrollment. It is worth mentioning that Fundamenta Therapeutics is conducting the maximum number of trials in this industry for different types of cancers, such as acute lymphoblastic leukemia, acute lymphoblastic lymphoma and non-Hodgkin’s lymphoma. In addition, an allogeneic CAR T cell therapy, ALLO-715 (developed by Allogene) for the treatment of relapsed / refractory multiple myeloma has demonstrated positive results in the Phase I clinical trials.
Market Trends Analysis: Partnerships and Collaborations have Fueled Allogenic Cell Therapy Market Growth
Several stakeholders have been forging alliances with other industry / non-industry players for the development of allogeneic cell therapies. It is worth highlighting that, since 2019, over 90 strategic partnerships have been established in the allogeneic cell therapy market. Majority of such deals are focused on research and development, product / technology licensing, and development and commercialization of allogenic cell therapies. In March 2023, Tessa Therapeutics entered into a research and development agreement with US National Cancer Institute for Tessa’s allogeneic CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, TT11X, useful in the treatment of non-Hodgkin’s lymphoma. In January 2022, Allogene Therapeutics signed a licensing agreement with Antion Biosciences for the latter company’s miRNA technology (miCAR™) in order to advance multiplex gene silencing tool (useful in the development of innovative allogeneic CAR T cell therapy).
Market Trends Analysis: Increase in Funding Reflect the Rising Interest in Allogenic Cell Therapy Market
The growing interest in allogeneic cell therapy market can be validated by the fact that in the past four years, close to USD 8.8 billion has been invested by several investors based across the globe, in companies engaged in the development of allogeneic cell therapies. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Legend Biotech raised the maximum funding amount (USD 487.3 million) through initial public offering. In December 2022, Gamida Cell announced the closing of a convertible term loan of USD 25 million with Highbridge Capital Management; the funding is planned to be used to advance the company’s allogeneic NK cell therapy pipeline.
Market Analysis: Global Allogeneic Cell Therapies Market Size
The global allogeneic cell therapy market is estimated to be worth USD 900 million in 2023. Driven by the increasing need for novel allogenic cell therapies, along with growing development pipeline and encouraging clinical trial results, the allogenic cell therapies market is anticipated to grow at a CAGR of 14% during the forecast period. Specifically, in terms of target disease indication, the market is anticipated to be driven by allogeneic cell therapies being developed for the treatment of lymphoma and leukemia.
Regional Analysis: North America to Hold the Largest Allogeneic Cell Therapy Market Share
Majority of the companies developing allogeneic cell therapies are headquartered in North America, followed by companies based in Asia Pacific. Consequently, more than 60% of the global market of allogeneic cell therapies is anticipated to be captured by players based in North America, in 2035. The factors responsible for the growth of the allogeneic cell therapy market in North America include the rising incidence of acute as well as chronic disorders, increasing FDA approvals for novel allogenic cell therapies and growing adoption of innovative therapies in the developed countries. In addition, the US government has been actively involved in providing reimbursement for expensive allogeneic cell therapies, recognizing their potential to revolutionize healthcare and improve patient outcomes.
Leading Allogeneic Cell Therapy Companies
Examples of the key allogeneic cell therapy companies (based on number of products under development; the complete list of players is available in the full report) include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics, Fundamenta Therapeutics, GC Cell, Hope Biosciences, Immunity Bio, Mesoblast, Nanjing Bioheng Biotech, Orca Bio, Pluristem Therapeutics, Poseida Therapeutics and Stemedica Cell Technologies. This market report also includes an easily searchable excel database of all the allogeneic therapy companies (developers) worldwide.
Scope of the Report
The market report presents an in-depth analysis of the various firms / organizations that are engaged in the allogenic cell therapy market, across different segments.
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the market report includes:
- An executive summary of the insights captured during our research. It offers a high-level view on the current state of allogeneic cell therapy market and its likely evolution in the mid-long term.
- A general overview of allogeneic cell therapy, along with information on their manufacturing process, key advantages, challenges and recent developments within this market.
- A detailed assessment of the overall landscape of allogeneic cell therapies, based on several relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, phase of development (preclinical, clinical and marketed), route of administration (intravenous, intraarticular, topical, intramuscular, intrathecal, subretinal, intracoronary, inhalational and others), type of cell therapy (stem cell therapies, T-cell therapies, NK cell therapies, dendritic cell therapies and others), source of cell (peripheral blood, umbilical cord, bone marrow and placenta), dosing frequency (single dose and multiple dose), type of therapy (monotherapies and combination therapies), target patient segment (children, adults and elderly patients), target indication (acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, B-cell lymphoma, COVID-19, osteoarthritis, acute respiratory distress syndrome, myelodysplastic syndrome, colorectal cancer and gastric cancer), and therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, infectious diseases, autoimmune / inflammatory disorders, post-transplant infections, cardiovascular disorders, respiratory disorders, cerebrovascular disorders, ophthalmic disorders, dermatological disorders, genetic disorders, kidney disorders, liver disorders, metabolic disorders and others).
- A detailed analysis of the partnerships established between stakeholders engaged in this industry, since 2019, covering research and development agreements, product / technology licensing agreements, product development and commercialization agreements, manufacturing / supply agreements, product development agreements, clinical trial agreements, mergers, acquisitions, product commercialization agreements and other relevant agreements.
- An analysis of the funding and investments that have been made into companies developing allogeneic cell therapies, which include venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place during the period 2019 to 2023, highlighting the growing interest of venture capital (VC) community and other strategic investors in this market.
- An analysis of completed and ongoing clinical trials related to allogeneic cell therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, study design, type of sponsor, geography, and most active industry and non-industry players (in terms of number of trials).
- An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to allogeneic cell therapies, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the allogeneic cell therapies market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of cell therapy (virus-specific T-cell, stem cell and regulatory T-cell), source of cell (peripheral blood, bone marrow, umbilical cord blood, adipose tissue and placenta), target indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, autoimmune / inflammatory disorders, post-transplant infections), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with some of the key industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is allogeneic cell therapy?
Answer: Allogeneic cell therapy involves the isolation of cells from a donor, followed by ex vivo manipulation and subsequent administration into the patients.
Question 2: What is allogenic vs autologous cell therapy?
Answer: Allogenic cell therapy refers to a cellular therapy in which the cells from a healthy donor are used to treat a patient while autologous cell therapy refers to a cellular therapy in which the cells are used from the patient’s peripheral blood.
Question 3: What are the advantages of allogeneic cell therapy?
Answer: Allogeneic cell therapy has various advantages, including availability as a scalable off-the-shelf product, diversity of cells or tissues, higher quality product, cost effectiveness and easy automation.
Question 4: What is an example of autologous cell therapy?
Answer: An example of autologous cell therapy is Epicel (developed by Genzyme Biosurgery) for the treatment of deep dermal or full thickness burns.
Question 5: Which are the most common sources from which allogeneic cells can be derived?
Answer: Allogeneic cell therapies can be derived through different sources, such as adipose tissue, amniotic sac, bone marrow, cord blood, peripheral blood and placenta.
Question 6: How many companies are developing allogeneic cell therapies?
Answer: At present, close to 195 companies claim to develop allogeneic cell therapies for different therapeutic areas. The majority of allogeneic cell therapies are stem cell therapies, followed by T-cell therapies (including CAR T cell, gamma delta T cell, virus-specific T cell, regulatory T cell, TCR and TIL).
Question 7: What are the partnership trends in the allogeneic cell therapies domain?
Answer: Research and development, product / technology licensing agreements, product development agreements, are the most common types of partnerships inked by stakeholders in this industry.
Question 8: How big is the global allogeneic cell therapies market?
Answer: The global market for allogeneic cell therapies is anticipated to be worth USD 0.9 billion in 2023.
Question 9: What is the likely growth rate (CAGR) of allogeneic cell therapy market?
Answer: The global allogeneic cell therapy market is expected to grow at a CAGR of 14% during the forecast period 2023 to 2035.
Question 10: Which region captures the largest market share of the allogeneic cell therapy market?
Answer: At present, the allogeneic cell therapies market is dominated by North America, capturing more than 60% of the overall market size.
Question 11: Which segment is likely to have the largest market share in the allogeneic cell therapy market?
Answer: Currently, the oncological disorders segment dominates the allogeneic cell therapy market.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 920th Hospital of Joint Logistics Support Force
- AbbVie
- Academisch Medisch Centrum
- Acepodia
- Adaptimmune Therapeutics
- Adicet Bio
- Aegle Therapeutics
- Affiliated Hospital to Academy of Military Medical Sciences
- Affimed
- Alaunos Therapeutics
- Allogene Therapeutics
- AlloVir
- Alpha Biopharma
- Altaco XXI
- Amgen
- Angiocrine Bioscience
- Anhui Provincial Hospital
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Anterogen
- Antion Biosciences
- APICES
- Athersys
- Artiva Biotherapeutics
- Astellas Pharma
- Atara Biotherapeutics
- Athenex
- Athersys
- Autolomous
- Azidus Brasil
- Bayer
- Baylor College of Medicine
- Baylx
- Be The Match BioTherapies
- Beijing 302 Hospital
- Beijing Doing Biomedical
- Beijing GD Initiative Cell Therapy Technology
- Beijing Immunochina Medical Science & Technology
- JD Biotech
- Beijing SH biotechnology
- Beth Israel Deaconess Medical Center
- BHI Therapeutic Sciences
- BioCardia
- Bioceltech Therapeutics
- BioCentriq
- Biomedical Advanced Research and Development Authority (BARDA)
- Biorasi
- Bioray Laboratories
- BioSenic (Previously known as Bone Therapeutics)
- Bristol Myers Squibb
- California Institute for Regenerative Medicine
- Cancer Research UK
- Capricor Therapeutics
- CardioCell
- Caribou Biosciences
- Cartesian Therapeutics
- Junta de Castilla y León
- Catalent Pharma Solutions
- Catamaran Bio
- Cedars-Sinai Medical Center
- Celixir
- Cell2Cure
- Cellavita
- Cell and Gene Therapy Catapult
- Cellectis
- Cellenkos
- Cellerant Therapeutics
- Cellerix
- Celltex Therapeutics
- Cellular Biomedicine Group (CBMG)
- Celularity
- Celyad Oncology
- Center for Breakthrough Medicines
- Central South University
- Centre Hospitalier Universitaire de Limoges
- Chabiotech
- Chandler Regional Medical Center
- Changhai Hospital
- Huaxia Intech (Biotech) Biotechnology (Previously known as China Immunotech Biotechnology)
- China-Japan Friendship Hospital
- Chinese Academy of Medical Sciences
- Chinese PLA General Hospital
- Cipla
- Citospin
- Cleveland Clinic
- Cliniques universitaires Saint-Luc
- CoImmune
- Copenhagen University Hospital
- Corestem
- CRISPR Therapeutics
- Cynata Therapeutics
- CytoMed Therapeutics
- Cytopeutics
- Cytora
- Cytovia Therapeutics
- Daewoong Pharmaceutical
- Department of Health and Human Services
- Deverra Therapeutics
- Direct Biologics
- DiscGenics
- Dt&SanoMedics
- Duke University
- EdiGene
- Editas Medicine
- ElevateBio
- ENCell
- Enlivex Therapeutics
- European Commission
- European Union
- Ever Supreme Bio Technology
- Fate Therapeutics
- Ferrer Internacional
- FGK Clinical Research
- FibroBiologics
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- Formula Pharmaceuticals
- Fortress Biotech
- Fred Hutchinson Cancer Center
- Fresno Community Hospital and Medical Center
- FUJIFILM Diosynth Biotechnologies
- Fundamenta Therapeutics
- Gamida Cell
- GC Cell
- Gemeinsamer Bundesausschuss
- Genentech
- GentiBio
- Genzyme
- Ghent University
- Global Cord Blood Corporation
- Glycostem Therapeutics
- Gracell Biotechnologies
- Granzer Regulatory Consulting & Services
- Greenlight Clinical
- Gwo xi Stem Cell
- GX Acquisition
- Qihan Biotech
- Hanyang University Medical Center
- HCW Biologics
- Hebei Yanda Ludaopei Hospital
- Help Therapeutics
- Henan Cancer Hospital
- Histocell
- Hope Biosciences
- Hospital Clínico Universitario de Valladolid
- Hospital del Río Hortega
- Hospital for Special Surgery
- Hospital Infantil Universitario Niño Jesús
- Hospital San Carlos
- Hospital Vera Cruz
- Huashan Hospital
- Hyundai Bioland
- iCAR Bio Therapeutics
- iCell Gene Therapeutics
- ICON plc
- Infectious Disease Research Institute (IDRI)
- IMAC Regeneration Centers
- Immunitybio
- Implant Therapeutics
- Imugene
- IN8bio
- Incyte
- inno.N
- Innovate UK
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
- Institute of Hematology & Blood Diseases Hospital
- Instituto de Salud Carlos III
- International Research Institute Servier
- Janssen
- JCR Pharmaceutical
- jCyte
- Jiangsu Topcel-KH Pharmaceutical
- Jinling Hospital
- JW Therapeutics
- Kadimastem
- Kangstem Biotech
- Karolinska Institutet
- Kinesiometrics
- KSQ Therapeutics
- Kuur Therapeutics
- Kyocera
- Legend Biotech
- LG Chem
- Lineage Cell Therapeutics
- Link Health
- Longeveron
- Lonza
- LUMICKS
- Lung Biotechnology PBC
- M.D. Anderson Cancer Center
- Magellan Stem Cells
- Magenta Therapeutics
- Masonic Cancer Center
- MaxCyte
- Mayo Clinic
- McGill University Health Centre
- Medac
- Medeor Therapeutics
- Medical University of South Carolina
- MEDIPOST
- Medpace
- Medsenic
- Memorial Sloan Kettering Cancer Center
- Mendus
- Merck Sharp & Dohme
- Mercy Gilbert Medical Center
- Mesoblast
- Ministerio de Ciencia e Innovacion
- Ministry of Health & Welfare (MOHW)
- Nanfang Hospital of Southern Medical University
- Nanjing Bioheng Biotech
- Nanjing Enricnk Biotech
- NantKwest
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Health Research and Development (NIHRD) (Indonesia)
- National University Hospital, Singapore
- Nature Cell
- Neurona Therapeutics
- NexImmune
- NextCell Pharma
- Nippon Shinyaku
- Nkarta Therapeutics
- Nohla Therapeutics
- Northern Therapeutics
- Novartis Pharmaceuticals
- NuVasive
- Ohio State University Comprehensive Cancer Center
- OmniaBio
- Oncternal Therapeutics
- Ono Pharmaceutical
- Orca Bio
- Orthofix
- Osiris Therapeutics
- Ossium Health
- Overland Pharmaceuticals
- Pandorum International
- PersonGen BioTherapeutics (Suzhou)
- Pfizer
- Pharmicell
- Phio Pharmaceuticals
- Pieris Pharmaceuticals
- Pierre Fabre
- Pluristem Therapeutics
- Poseida Therapeutics
- PPD
- Precision BioSciences
- Precision Biotech
- Pregene
- ProMab Biotechnologies
- Promethera Biosciences
- Protech Pharmaservices
- PT Prodia StemCell Indonesia (ProSTEM)
- Pulthera
- Q Therapeutics
- Quintiles
- R3 Stem Cell
- Red de Terapia Celular
- Regeneus
- ReNeuron
- Renji Hospital
- Renmin Hospital of Wuhan University
- Restem
- resTORbio
- RHEACELL
- Rigenerand
- Rigshospitalet
- Roche
- Royal Brompton and Harefield hospitals
- Ruijin Hospital
- S.Biomedics
- Salvat
- Sanofi
- Santen Pharmaceutical
- Sclnow Biotechnology
- SCM Lifescience
- Second Affiliated Hospital of Xi'an Jiaotong University
- Sentien Biotechnologies
- Seoul CRO
- Servier
- Shanghai Changzheng Hospital
- Shanghai East Hospital
- Shanghai GeneChem
- Shanghai General Hospital
- Shanghai iCELL Biotechnology
- Shanghai Jiao Tong University School of Medicine
- Shanghai Ninth People's Hospital
- Shanghai Public Health Clinical Center
- Shanghai Sixth People's Hospital
- Shenzhen Pregene Biopharma
- Shenzhen University General Hospital
- Shire
- SK Bioland
- SMT Bio
- Sorrento Therapeutics
- Springworks
- Staburo
- Stanford University
- Stemedica Cell Technologies
- Steminent Biotherapeutics
- Stempeutics Research
- Taiga Biotechnologies
- Taipei Veterans General Hospital
- Taiwan Bio Therapeutics
- Talaris Therapeutics
- Tang-Du Hospital
- TC BioPharm
- Teijin Pharma
- Tel Aviv Sourasky Medical Center
- Tessa Therapeutics
- Tevogen Bio
- The Affiliated Hospital of Guizhou Medical University
- The Affiliated Hospital of Xuzhou Medical University
- The Affiliated Union Hospital of Fujian Medical University
- The Cleveland Clinic
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Henan University of Science and Technology
- The First Affiliated Hospital of Kunming Medical College
- The First Affiliated Hospital of Soochow University
- The First Affiliated Hospital of University of Science and Technology of China
- The First Affiliated Hospital of Zhengzhou University
- The First People's Hospital of Hefei
- The Foundation for Orthopaedics and Regenerative Medicine
- The General Hospital of Western Theater Command
- The Marcus Foundation
- The Methodist Hospital Research Institute
- The Netherlands Organisation for Health Research and Development
- The Second Affiliated Hospital of Chongqing Medical University
- The Second Hospital of Shandong University
- The University of Texas Health Science Center
- The University of Texas MD Anderson Cancer Center
- Thomas Jefferson University
- TICEBA
- TiGenix (Acquired by Takeda)
- Timmune Biotech
- Tiziana Life Sciences
- Translational Biosciences
- Trinity College Dublin
- Tri-Service General Hospital
- Triumvira Immunologics
- Tscan Therapeutics
- Twist Bioscience
- UCI Medical Center
- UMC Utrecht
- UnicoCell Biomed
- Universitätsklinikum Hamburg-Eppendorf
- Universiti Kebangsaan Malaysia Medical Centre
- Universiti Tunku Abdul Rahman
- University Medical Center Groningen
- University of California
- University of Florida
- University of Kansas Medical Center
- University of Louisville
- University of Miami
- University of Minnesota
- University of Munich
- University of Sydney
- University of Valladolid
- University of Wisconsin-Madison
- Uppsala University
- National Cancer Institute
- Utooth Biological Technology
- VetStem Biopharma
- ViaCyte
- ViGenCell
- Vinmec Research Institute of Stem Cell and Gene Technology
- Vinnova
- Virginia Contract Research Organization
- Viscofan
- Vitro Biopharma
- Washington University
- Wugen
- Wuhan Jinyintan Hospital
- Xindu (A subsidiary of Xintela)
- Xinqiao Hospital of Chongqing
- Xintela
- Xuzhou Medical University
- Zelluna Immunotherapy
- Zhejiang University
- Zhengzhou University
Methodology
LOADING...